

## Obtaining procedure of SnO<sub>2</sub> photoelectrodes using picosecond laser with dye sensitized solar cells applications


NATIONAL INSTITUTE FOR LASER, PLASMA AND RADIATION PHYSICS

National PATENT APPLICATION A100226/06.05.2021

Inventors: Cornelia Enache, Cristian Viespe

**ABSTRACT:** The invention refers to one procedure of obtaining in situ of SnO<sub>2</sub> photoelectrodes (nanoporous films) using a picosecond laser by laser ablation method with DSSC (dye sensitized solar cells) applications. This type of photoelectrodes (SnO<sub>2</sub>) have the advantage of high electrons mobility, high absorption in red-IR domain, larger band gap. Nanoporous SnO<sub>2</sub> films obtained in situ meet the requirements of a photoelectrode from morphological point of view, in terms of adhesion and composition, for obtaining DSSC.

**CLAIMS:** Obtaining procedure of SnO<sub>2</sub> photoelectrodes by laser ablation using picosecond laser characterized by the fact that we obtained in situ nanoporous films that meet the requirements of a photoelectrode in terms of morphology, adhesion, composition for dye sensitized solar cells (DSSC) applications.



A laser beam (3) emitted by a ps laser (2) computer controlled (1) is focused on the focus lens (4) and then passes through the window (5) placed at the entrance of the deposition chamber (6) and focused onto the target (7) (tin metal). Following the interaction of the laser beam (3) – target (7) an ablation plume (9) is formed which is deposited onto FTO (fluorine doped tin oxide) substrate (10). During the deposition process, the target is moved by a motorized X-Y translation system (8) computer controlled (15). Before deposition, the deposition chamber (6) is evacuated by a high vacuum turbomolecular pump (12); during the deposition in the chamber is introduced gas from the gas cylinder (14) with a constant flow controlled by a system (15). The desired working pressure is maintained in the deposition chamber (6) by a valve (17) controlled by a controller (18) connected to a preliminary vacuum pump (16). After deposition, the films were treated in oxygen atmosphere in an oven connected to the gas cylinder.

**ACKNOWLEDGMENTS:** THIS WORK WAS SUPPORTED BY A GRANT OF THE ROMANIAN MINISTRY OF RESEARCH AND INNOVATION, CCCDI-UEFISCDI PROJECT NUCLEU contact: NILPRP, Laser Department, Quantum Dots, Nanopowders and Thin Films Group, <http://qdntf.inflpr.ro/>  
Dr. C. Enache (cornelia.sima@inflpr.ro), Dr. C. Viespe (cristian.viespe@inflpr.ro)

## Discriminative detection method of analytes using surface acoustic wave sensors in a tunable oscillatory circuit.



NATIONAL INSTITUTE FOR LASER, PLASMA AND RADIATION PHYSICS

National PATENT APPLICATION A00337/15-06-2021

Inventors: Nicolae Ionut, Marcu Aurelian, Viespe Cristian, Miu Dana

**ABSTRACT:** The invention refers to a method of analytes discrimination based on the frequency deviation measurement of a tunable oscillatory circuit, having a surface acoustic wave sensor (SAW) connected in its positive reaction loop. The fundamental operating frequency is controlled by adjusting the value of an adjustable resistance placed within the oscillator amplifier feedback loop. The control of the gas composition in the SAW sensor chamber is achieved by introducing a known quantity of the analyte in a synthetic air atmosphere. Thus, in the presence of an analyte, the oscillator circuit frequency will change from its fundamental frequency, depending on the quantity and type of the analyte, but also depending on the chosen fundamental frequency of oscillation.

**CLAIMS:** The analyte discrimination method, it discriminates between analytes using the same type of sensor, without the need to use specific (different) sensors for each individual analyte. Method is based on surface acoustic wave sensors (SAW) frequency deviation, in the presence of analytes, is measured at several fundamental (free) oscillation frequencies.



Frequency shift variation on circuit base (free) oscillation frequency

**ACKNOWLEDGMENTS:** THIS WORK WAS SUPPORTED BY A GRANT OF THE ROMANIAN MINISTRY OF RESEARCH AND INNOVATION, CCCDI-UEFISCDI PROJECT NUCLEU contact: NILPRP, Laser Department, Quantum Dots, Nanopowders and Thin Films Group, <http://qdntf.inflpr.ro/>  
Dr. I. Nicolae (ionut.nicolae@inflpr.ro), Dr. C. Viespe (cristian.viespe@inflpr.ro)





## Technical Field


The OSIM Patent Application no. A-06409/22.08.2024, S25 under A61P, SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS (C51H0 Antineoplastic agents).

## Problem Addressed

Current cancer therapies face challenges like drug resistance and high toxicity to healthy cells. This method offers a selective approach to reduce side effects and improve treatment outcomes.

## Technical Solution

This invention proposes a targeted cancer therapy using chlorpromazine (CPZ), a phenothiazine-class drug, activated by 266 nm Nd:YAG laser irradiation. Post-irradiation samples were analyzed via UV-Vis, FTIR, and HPLC-MS to identify photoproducts. Molecular docking predicted interactions with cancer-specific targets. In vitro testing (MTS, Live/Dead, LDH) confirmed the potential of laser-activated CPZ as a selective anticancer agent. Laser irradiation transforms CPZ into photoproducts that show strong interaction with cancer-specific targets (proliferase and eIF). These compounds demonstrated selective cytotoxicity in vitro.



## Advantages

- Higher selectivity for cancer cells
- Lower effective drug doses
- Reduced side effects
- Potential to overcome drug resistance
- Utilizes an existing, well-studied drug
- Cost-effective and scalable for clinical use

## KEY FINDINGS

Laser irradiation induces the formation of photoproducts, and the duration of irradiation affects the appearance of specific photoproducts.


Moreover, the HPLC-MS analysis shows formation of several photoproducts (C264-072, C264-073, C264-074, C264-075, C264-076, C264-077, C264-078, C264-079, C264-080, C264-081, C264-082, C264-083, C264-084, C264-085, C264-086, C264-087, C264-088, C264-089, C264-090, C264-091, C264-092, C264-093, C264-094, C264-095, C264-096, C264-097, C264-098, C264-099, C264-100).

Although CPZ and the monomeric photoproducts show low predicted binding energies, the dimeric compounds exhibit even lower binding affinities, with C264-072 showing the most favorable interaction energy (-11.31 kcal/mol).

CPZ's toxicity depended on the duration of irradiation and treatment dose, with the most significant effect after 40 min of irradiation.


Irradiated CPZ induced cell death in both cell types, with a more pronounced effect in tumour cells, indicating possible selectivity for cancer cells over normal cells. Irradiated CPZ caused membrane disruption and significant *F*-actin cytoskeleton changes [1].

[1] Udrea, A.M., Stăicu, A., Smarandache, A., et al. Enhancement of chlorpromazine efficacy in breast cancer treatment by 266 nm laser irradiation. Sci Rep 14, 35329 (2024).




Abundance of CPZ and its photoproducts.


Abundance of high m/z photoproducts of chlorpromazine irradiated over the course of 60 min.




3D interaction of photoproducts (C264-072) with the eIF4E receptor in the form of the lowest EFEE.




Biological targets and the lowest EFEE for CPZ and its photoproducts, predicted using Autodock software.



Cellular viability levels were assessed, and significant results were indicated by error bars representing standard deviation with  $p < 0.05$ ,  $p < 0.01$ ,  $p < 0.001$ .



Fluorescence microscopy images showing MCF-12A and MCF-7 cells. Viability of cells is marked with green fluorescence, while dead cells are marked with red fluorescence. The scale bar represents 100 μm.



Fluorescent labeling of *F*-actin filaments present in MCF-12A and MCF-7 cells using phalloidin FIC. The scale bar represents 50 μm.